Targeted destruction of androgen‐sensitive and ‐insensitive prostate cancer cells and xenografts through luteinizing hormone receptors

We have prepared a conjugate of a lytic peptide (hecate) and a 15‐amino acid segment of the β‐chain of LH to test the concept that this conjugate will target cancer cells expressing LH receptors.

[1]  G. Steiner,et al.  Coexpression of gonadotropic hormones and their corresponding FSH‐ and LH/CG‐receptors in the human prostate , 1998, The Prostate.

[2]  C. Wood,et al.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. , 1998, British Journal of Cancer.

[3]  M. Wilson,et al.  Human prostate tumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells , 1997, The Anatomical record.

[4]  M. Llanos,et al.  Arachidonic acid release from rat Leydig cells depends on the presence of luteinizing hormone/human chorionic gonadotrophin receptors. , 1997, The Journal of endocrinology.

[5]  D. Grainger,et al.  Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. , 1997, Circulation.

[6]  R. Gopalakrishna,et al.  Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells* , 1996, The Journal of Biological Chemistry.

[7]  D. D'Amico,et al.  Multiple Estrogen Function in Human Prostate Cancer Cells a , 1996, Annals of the New York Academy of Sciences.

[8]  H. Shi,et al.  A role for increased lutropin/choriogonadotropin receptor (LHR) gene transcription in the follitropin-stimulated induction of the LHR in granulosa cells. , 1995, Molecular endocrinology.

[9]  E. Reiter,et al.  Expression and functionality of luteinizing hormone/chorionic gonadotropin receptor in the rat prostate. , 1995, Endocrinology.

[10]  R. Campbell,et al.  Co-evolution of ligand-receptor pairs , 1994, Nature.

[11]  P. Roche,et al.  A receptor binding site identified in the region 81–95 of the β-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG) , 1993, Molecular and Cellular Endocrinology.

[12]  M. Ascoli,et al.  Epidermal growth factor, a phorbol ester, and 3',5'-cyclic adenosine monophosphate decrease the transcription of the luteinizing hormone/chorionic gonadotropin receptor gene in MA-10 Leydig tumor cells. , 1992, Endocrinology.

[13]  M. Benahmed,et al.  Sites of interaction between epidermal growth factor and transforming growth factor-beta 1 in the control of steroidogenesis in cultured porcine Leydig cells. , 1992, Endocrinology.

[14]  A. Schally,et al.  Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. , 1990, Endocrinology.

[15]  J. Richards,et al.  Hormonal regulation of luteinizing hormone/chorionic gonadotropin receptor mRNA in rat ovarian cells during follicular development and luteinization. , 1990, Molecular endocrinology.

[16]  J. Emmett,et al.  Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies. , 1960, Transactions of the American Association of Genito-Urinary Surgeons.

[17]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[18]  C. Rao,et al.  Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans. , 1997, Biology of reproduction.

[19]  W. Maloy,et al.  Structure–activity studies on magainins and other host defense peptides , 1995, Biopolymers.

[20]  H. Haigler.  [22] Receptor-mediated endocytosis of epidermal growth factor , 1983 .